Ali Ziaolhagh and Christos Argyropoulos: SGLT2 Inhibitors across the Spectrum of Severity of CKD. Clin J Am Soc Nephrol 15: 1386–1388, 2020; published ahead of print October 7, 2020, doi: https://doi.org/10.2215/CJN.13430820
In Figure 1A and B, the kidney failure category was mislabeled as ≥ 15 ml/min per 1.73 m2 instead of ≤. The corrected figure appears below.
Figure 1.
Kidney-specific outcomes of SGLT2i in diabetic kidney disease. Hazard ratio (HR) of empagliflozin on MACE-3 (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke; A) and incident/worsening nephropathy (B) by Kidney Disease Improving Global Outcomes (KDIGO) risk category in EMPA-REG OUTCOME; years of postponed kidney failure in the very high risk KDIGO category associated with the use of empagliflozin in EMPA-REG OUTCOME by pretherapy eGFR (C); and meta-analysis of the composite kidney disease outcome of worsening kidney function/ESKD and kidney death across kidney disease outcomes (CREDENCE), cardiovascular safety (CANVAS Program, DECLARE-TIMI-58, EMPA-REG, VERTIS-CV), and heart failure (DAPA-HF) in sodium glucose cotransporter 2 inhibitor (SGLT2i) trials (D). 95% CI, 95% confidence interval; PBO, placebo; PY, person years.
Footnotes
Published online ahead of print. Publication date available at www.cjasn.org.
See original article, “SGLT2 Inhibitors across the Spectrum of Severity of CKD,” in Vol. 15, Iss. 10, 1386–1388.